BCM
BMY icon

Brooktree Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Brooktree Capital Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-230
Closed -$13K – 57
2020
Q1 		$13K Hold
230
– – 0.02% 93
2019
Q4 		$15K Buy
+230
New +$13.2K 0.01% 89

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Brooktree Capital Management's BMY Position: Q2 2020 in Review

Brooktree Capital Management sold out of Bristol-Myers Squibb (BMY) in Q2 2020, closing a stake of 230 shares — an estimated $13K sold.

Brooktree Capital Management first reported a position in BMY in Q4 2019 and held it in 2 quarters. The position peaked at $15K in Q4 2019. 2,189 funds tracked by Wall St. Rank hold BMY as of Q2 2020.

  • Brooktree Capital Management reported no remaining Bristol-Myers Squibb position as of Q2 2020 after selling out during the quarter.
  • Brooktree Capital Management sold 230 Bristol-Myers Squibb shares in Q2 2020, an estimated $13K.
  • Brooktree Capital Management first reported a position in Bristol-Myers Squibb in Q4 2019 and held it in 2 quarters.
  • Brooktree Capital Management's Bristol-Myers Squibb position peaked at $15K in Q4 2019.
  • 2,189 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2020.

Based on Brooktree Capital Management's 13F filing for Q2 2020, filed 3 Aug 2020.